Arca Biopharma Stock Today
| ABIO Stock | USD 3.63 0.02 0.55% |
Performance11 of 100
| Odds Of DistressLess than 38
|
ARCA Biopharma is selling at 3.63 as of the 25th of April 2024; that is -0.55 percent down since the beginning of the trading day. The stock's open price was 3.65. ARCA Biopharma has about a 38 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Equity ratings for ARCA Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of August 1997 | Category Healthcare | Classification Health Care |
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. The company was incorporated in 2004 and is headquartered in Westminster, Colorado. Arca Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 14.5 M outstanding shares of which 5.66 M shares are presently shorted by private and institutional investors with about 7.31 trading days to cover. More on ARCA Biopharma
Moving together with ARCA Stock
| 0.73 | ELYM | Eliem Therapeutics | PairCorr |
| 0.93 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.77 | CGC | Canopy Growth Corp Trending | PairCorr |
Moving against ARCA Stock
| 0.87 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.79 | GILD | Gilead Sciences Earnings Call Today | PairCorr |
| 0.71 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
ARCA Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. ARCA Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding ARCA Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Michael Bristow | ||||
| Old Names | [Albioma SA, Absalon Invest - Obligationer] | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
ARCA Biopharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to ARCA Biopharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ARCA Biopharma's financial leverage. It provides some insight into what part of ARCA Biopharma's total assets is financed by creditors.
| |||||
ARCA Biopharma (ABIO) is traded on NASDAQ Exchange in USA. It is located in 10170 Church Ranch Way, Westminster, CO, United States, 80021 and employs 4 people. ARCA Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 52.93 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ARCA Biopharma's market, we take the total number of its shares issued and multiply it by ARCA Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. ARCA Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 14.5 M outstanding shares of which 5.66 M shares are presently shorted by private and institutional investors with about 7.31 trading days to cover.
ARCA Biopharma currently holds about 46.44 M in cash with (5.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22.
Check ARCA Biopharma Probability Of Bankruptcy
Ownership AllocationThe market capitalization of ARCA Biopharma is $52.93 Million. The majority of ARCA Biopharma outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to acquire positions in ARCA Biopharma to benefit from reduced commissions. Thereupon, outside corporations are subject to a different set of regulations than regular investors in ARCA Biopharma. Please pay attention to any change in the institutional holdings of ARCA Biopharma as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check ARCA Ownership Details
ARCA Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of ARCA Biopharma jumping above the current price in 90 days from now is about 1.2%. The ARCA Biopharma probability density function shows the probability of ARCA Biopharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.8167. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, ARCA Biopharma will likely underperform. Moreover, aRCA Biopharma has an alpha of 1.4928, implying that it can generate a 1.49 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of ARCA Biopharma to move above the current price in 90 days from now is about 1.2 (This ARCA Biopharma probability density function shows the probability of ARCA Stock to fall within a particular range of prices over 90 days) .
ARCA Stock Institutional Holders
Institutional Holdings refers to the ownership stake in ARCA Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ARCA Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ARCA Biopharma's value.| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2023-12-31 | 21 K | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 15 K | |
| Two Sigma Securities, Llc | 2023-12-31 | 12.1 K | |
| Tower Research Capital Llc | 2023-12-31 | 3 K | |
| Ubs Group Ag | 2023-12-31 | 1.1 K | |
| Parallel Advisors, Llc | 2023-12-31 | 244 | |
| Simplex Trading, Llc | 2023-12-31 | 100.0 | |
| Wells Fargo & Co | 2023-12-31 | 79.0 | |
| Royal Bank Of Canada | 2023-12-31 | 56.0 | |
| Cable Car Capital Llc | 2023-12-31 | 4 M | |
| Western Standard Llc | 2023-12-31 | 1.4 M |
ARCA Biopharma Historical Income Statement
ARCA Biopharma Income Statement is one of the three primary financial statements used for reporting ARCA's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of ARCA Biopharma revenue and expense. ARCA Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, ARCA Biopharma's Interest Expense is very stable compared to the past year. As of the 25th of April 2024, Selling General Administrative is likely to grow to about 7.2 M, while Depreciation And Amortization is likely to drop about 105.5 K. View More FundamentalsARCA Stock Against Markets
Picking the right benchmark for ARCA Biopharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in ARCA Biopharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for ARCA Biopharma is critical whether you are bullish or bearish towards ARCA Biopharma at a given time. Please also check how ARCA Biopharma's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in ARCA Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
ARCA Biopharma Corporate Directors
ARCA Biopharma corporate directors refer to members of an ARCA Biopharma board of directors. The board of directors generally takes responsibility for the ARCA Biopharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of ARCA Biopharma's board members must vote for the resolution. The ARCA Biopharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Raymond Woosley | Director | Profile | |
| Daniel Mitchell | Director | Profile | |
| Linda Grais | Lead Independent Director | Profile | |
| Anders Hove | Director | Profile |
How to buy ARCA Stock?
Before investing in ARCA Biopharma, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in ARCA Biopharma. To buy ARCA Biopharma stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of ARCA Biopharma. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase ARCA Biopharma stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located ARCA Biopharma stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased ARCA Biopharma stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as ARCA Biopharma, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy ARCA Stock please use our How to Invest in ARCA Biopharma guide.
Already Invested in ARCA Biopharma?
The danger of trading ARCA Biopharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ARCA Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ARCA Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ARCA Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ARCA Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ARCA Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arca Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arca Biopharma Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for ARCA Stock analysis
When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Return On Assets (0.11) | Return On Equity (0.14) |
The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.